September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30
~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT
ANNEXON BIOSCIENCES REPORTS PHASE 2 CLINICAL TRIAL RESULTS DEMONSTRATING UPSTREAM CLASSICAL COMPLEMENT INHIBITION ASSOCIATED WITH CLINICAL BENEFIT IN HUNTINGTON’S DISEASE On June 7, Annexon, that is a clinical-stage biopharmaceutical company
May Awareness Month 2022 came to an end. Between the webinars, weekends away and Light It Up For HD, there were a lot of initiatives coming from all the different
To finish May Awareness Month in the most inspiring and hopeful way possible, the International Huntington Association and European Huntington Association had a webinar with Dimitri Poffé, a Huntington’s Disease
It’s HD May Awareness Month and HDSI (Huntington’s Disease Society of India) is celebrating it with HD light-up, by lighting up buildings of proeminence in order to express solidarity with
If the situation in Ukraine isn’t desperate enough, spare a thought for those with the added burden of Huntington’s Disease. Danuta Lis, president of the Polish HD Association and Bea De
Yesterday, Prilenia hosted a webinar updating on the Phase III trial with Pridopidine. Thank you to everyone who join and a special thanks to our speakers, Michael Hayden, Andrew Feigin,
HDYO will launch JOIN-HD, the Juvenile onset HD Global Registry, that will be open for Stage 1: Open Enrollment, starting February 4th. JOIN-HD is a global registry that collects experiences
Some encouraging news has just come in from Roche. Analysis of the results of Roche’s Phase III GENERATION HD1 trial, which was stopped in March 2021, has found that a
September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30
~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT
ANNEXON BIOSCIENCES REPORTS PHASE 2 CLINICAL TRIAL RESULTS DEMONSTRATING UPSTREAM CLASSICAL COMPLEMENT INHIBITION ASSOCIATED WITH CLINICAL BENEFIT IN HUNTINGTON’S DISEASE On June 7, Annexon, that is a clinical-stage biopharmaceutical company
May Awareness Month 2022 came to an end. Between the webinars, weekends away and Light It Up For HD, there were a lot of initiatives coming from all the different
To finish May Awareness Month in the most inspiring and hopeful way possible, the International Huntington Association and European Huntington Association had a webinar with Dimitri Poffé, a Huntington’s Disease
It’s HD May Awareness Month and HDSI (Huntington’s Disease Society of India) is celebrating it with HD light-up, by lighting up buildings of proeminence in order to express solidarity with
If the situation in Ukraine isn’t desperate enough, spare a thought for those with the added burden of Huntington’s Disease. Danuta Lis, president of the Polish HD Association and Bea De
Yesterday, Prilenia hosted a webinar updating on the Phase III trial with Pridopidine. Thank you to everyone who join and a special thanks to our speakers, Michael Hayden, Andrew Feigin,
HDYO will launch JOIN-HD, the Juvenile onset HD Global Registry, that will be open for Stage 1: Open Enrollment, starting February 4th. JOIN-HD is a global registry that collects experiences
Some encouraging news has just come in from Roche. Analysis of the results of Roche’s Phase III GENERATION HD1 trial, which was stopped in March 2021, has found that a
English English 
Arabic
Bulgarian
Chinese
Czech
Danish
Dutch
Estonian
Finnish
French
German
Greek
Hungarian
Indonesian
Italian
Japanese
Latvian
Lithuanian
Polish
Portuguese
Romanian
Russian
Slovak
Slovenian
Spanish
Swedish
Turkish
Ukrainian
